Ignite Creation Date:
2024-05-06 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05735327
Status:
RECRUITING
Last Update Posted:
2023-09-05
First Post:
2023-02-10
Brief Title:
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer NSCLC ENTIRETY
Sponsor:
Organization:
Takeda
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
False
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
SAMPLES_WITH_DNA
Bio Spec Description:
Biospecimen collected would be blood samples
Enrollment Count:
50
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Cohort |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 92867 |
Who Masked List: